{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:06:57Z","timestamp":1784020017431,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society, Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10549-026-07969-7","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:04:11Z","timestamp":1776391451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Provider level facilitators and barriers towards neoadjuvant chemotherapy for triple negative and HER2\u2009+\u2009breast cancer: a survey of Ontario surgeons"],"prefix":"10.1007","volume":"217","author":[{"given":"Gary","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwyn","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Coburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J. Look","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"7969_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.5410","volume":"155","author":"M Golshan","year":"2020","unstructured":"Golshan M, Loibl S, Wong SM et al (2020) Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surg 155:e195410. https:\/\/doi.org\/10.1001\/jamasurg.2019.5410","journal-title":"JAMA Surg"},{"key":"7969_CR2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1200\/JCO.2004.09.062","volume":"22","author":"AM Chen","year":"2004","unstructured":"Chen AM, Meric-Bernstam F, Hunt KK et al (2004) Breast conservation after neoadjuvant chemotherapy: the M.D. anderson cancer center experience. J Clin Oncol 22:2303\u20132312. https:\/\/doi.org\/10.1200\/JCO.2004.09.062","journal-title":"J Clin Oncol"},{"key":"7969_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455\u20131461. https:\/\/doi.org\/10.1001\/jama.2013.278932","journal-title":"JAMA"},{"key":"7969_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"J-F Boileau","year":"2015","unstructured":"Boileau J-F, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol Off J Am Soc Clin Oncol 33:258\u2013264. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7969_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609\u2013618. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9","journal-title":"Lancet Oncol"},{"key":"7969_CR6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1245\/s10434-010-1390-8","volume":"18","author":"AS Caudle","year":"2011","unstructured":"Caudle AS, Gonzalez-Angulo AM, Hunt KK et al (2011) Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol 18:932\u2013938. https:\/\/doi.org\/10.1245\/s10434-010-1390-8","journal-title":"Ann Surg Oncol"},{"key":"7969_CR7","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S et al (2017) Adjuvant Capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147\u20132159. https:\/\/doi.org\/10.1056\/NEJMoa1612645","journal-title":"N Engl J Med"},{"key":"7969_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS et al (2019) Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017","journal-title":"N Engl J Med"},{"key":"7969_CR9","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A et al (2020) Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res Off J Am Assoc Cancer Res 26:2838\u20132848. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"7969_CR10","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"7969_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"7969_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi S, Salgado R, Curigliano G et al (2025) Neoadjuvant Nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med 31:433\u2013441. https:\/\/doi.org\/10.1038\/s41591-024-03414-8","journal-title":"Nat Med"},{"key":"7969_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, O\u2019Shaughnessy J, Liu Z et al (2025) Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial. Nat Med 31:442\u2013448. https:\/\/doi.org\/10.1038\/s41591-024-03415-7","journal-title":"Nat Med"},{"key":"7969_CR14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485\u20131505. https:\/\/doi.org\/10.1200\/JCO.20.03399","journal-title":"J Clin Oncol"},{"key":"7969_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-022-06522-6","volume":"193","author":"S Gandhi","year":"2022","unstructured":"Gandhi S, Brackstone M, Hong NJL et al (2022) A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat 193:1\u201320. https:\/\/doi.org\/10.1007\/s10549-022-06522-6","journal-title":"Breast Cancer Res Treat"},{"key":"7969_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-024-07282-1","volume":"206","author":"A Roberts","year":"2024","unstructured":"Roberts A, Hallet J, Nguyen L et al (2024) Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care. Breast Cancer Res Treat 206:227\u2013244. https:\/\/doi.org\/10.1007\/s10549-024-07282-1","journal-title":"Breast Cancer Res Treat"},{"key":"7969_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.breast.2014.01.008","volume":"23","author":"J van Hoeve","year":"2014","unstructured":"van Hoeve J, de Munck L, Otter R et al (2014) Quality improvement by implementing an integrated oncological care pathway for breast cancer patients. Breast 23:364\u2013370. https:\/\/doi.org\/10.1016\/j.breast.2014.01.008","journal-title":"Breast"},{"key":"7969_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10549-018-4954-0","volume":"173","author":"JM Neuner","year":"2019","unstructured":"Neuner JM, Kong A, Blaes A et al (2019) The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Res Treat 173:179\u2013188. https:\/\/doi.org\/10.1007\/s10549-018-4954-0","journal-title":"Breast Cancer Res Treat"},{"key":"7969_CR19","unstructured":"The American Association for Public Opinion (2011) American Association for Public Opinion Research Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. Deerfield, IL"},{"key":"7969_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant Paclitaxel and Trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1406281","journal-title":"N Engl J Med"},{"key":"7969_CR21","unstructured":"Pembrolizumab (Keytruda). https:\/\/canjhealthtechnol.ca\/index.php\/cjht\/article\/download\/PC0279\/920?inline=1. Accessed 10 Feb 2026"},{"key":"7969_CR22","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1245\/s10434-021-10519-8","volume":"28","author":"DW Lim","year":"2021","unstructured":"Lim DW, Greene BD, Look Hong NJ (2021) Relationship between breast and axillary pathologic complete response in women receiving neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 28:5495\u20135506. https:\/\/doi.org\/10.1245\/s10434-021-10519-8","journal-title":"Ann Surg Oncol"},{"key":"7969_CR23","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/jca.62830","volume":"12","author":"S-C Chen","year":"2021","unstructured":"Chen S-C, Yu C-C, Chang H-K et al (2021) Discrepancy of breast and axillary pathologic complete response and outcomes in different subtypes of node-positive breast cancer after neoadjuvant chemotherapy. J Cancer 12:5365\u20135374. https:\/\/doi.org\/10.7150\/jca.62830","journal-title":"J Cancer"},{"key":"7969_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24757-7","volume":"12","author":"J Lee","year":"2022","unstructured":"Lee J, Park NJ-Y, Park HY et al (2022) Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer. Sci Rep 12:21535. https:\/\/doi.org\/10.1038\/s41598-022-24757-7","journal-title":"Sci Rep"},{"key":"7969_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93203-1","volume":"15","author":"EC Yildirim","year":"2025","unstructured":"Yildirim EC, Atag E, Semiz HS et al (2025) Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy. Sci Rep 15:9866. https:\/\/doi.org\/10.1038\/s41598-025-93203-1","journal-title":"Sci Rep"},{"key":"7969_CR26","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1200\/JCO.21.00089","volume":"39","author":"S Rostoft","year":"2021","unstructured":"Rostoft S, O\u2019Donovan A, Soubeyran P et al (2021) Geriatric assessment and management in cancer. J Clin Oncol 39:2058\u20132067. https:\/\/doi.org\/10.1200\/JCO.21.00089","journal-title":"J Clin Oncol"},{"key":"7969_CR27","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1245\/s10434-021-11103-w","volume":"29","author":"L Cadili","year":"2022","unstructured":"Cadili L, DeGirolamo K, Ma CS-Y et al (2022) The breast cancer patient experience of telemedicine during COVID-19. Ann Surg Oncol 29:2244\u20132252. https:\/\/doi.org\/10.1245\/s10434-021-11103-w","journal-title":"Ann Surg Oncol"},{"key":"7969_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00392","author":"AP Shah","year":"2025","unstructured":"Shah AP, Shi S, Sun TY et al (2025) Virtual second-opinion delivery for oncology patients. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/OP.24.00392","journal-title":"JCO Oncol Pract"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07969-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07969-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07969-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:17Z","timestamp":1784017817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07969-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7969"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07969-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"20"}}